Small Cap Feast
Small Cap Feast – 30 June 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
The pantry is bare!
Entertainment AI 27p £13.5m (EAI.L)
The global social media and technology platform for sharing video moments to enable discovery, sharing and e-commerce through the connecting and targeting of creators, audiences and brands, announced both the release of its CreatorSuite product and its name change from Entertainment AI to SEEEN plc with ticker symbol SEEN to better reflect its technology brand and initiation of commercial product releases. CreatorSuite has, among its functionalities, the following three technological features:
- CreatorSuiteh elps creators produce short and attractive audio-visual content that attracts the users’ attention and can be viewed and acted on in the moment.
- CreatorSuite helps automate the generation of tailored versions of video content for publication on social platforms, in search engine results and across social media and communications networks.
- CreatorSuite helps increase findability with AI/ML-suggested tagging.
eEnergy 6p £7.9m (EAAS.L)
Update on trading for the financial year ending 30 June 2020. Since April, the business has secured 18 contracts with schools in the UK and Ireland., with a total contract value of EUR1.6 million. eLight has completed installations at 23 schools, recognising revenue of EUR1.4 million. Also, eLight has evolved its service offering to include a COVID-19 package for schools. This package will ensure customers are also able to sanitise their buildings effectively. The package has proved popular and has enabled the Group to progress several new opportunities with interested schools.
As such, for the quarter ended 30 June 2020, the Group expects to have recognised unaudited revenues of EUR2.1 million – an increase of over 40% compared to the comparable quarter of the prior year. Unaudited revenues for the full year ended 30 June 2020 are expected to be EUR5.1 million (audited 2019: EUR4.5 million).
IQGeo Group 60.5p £30m (IQG.L)
Significant expansion in software licenses across new teams within one of Canada’s largest telecoms network operators. This latest contract has an overall value of CAD 1.2m (GBP 0.7m) including increased software licence subscriptions and subscription renewals to be recognised over the next two years, together with additional implementation services to be recognised in the next year.
Redx Pharma 19.5p £37m (REDX.L)
The drug discovery and development Group focused on cancer and fibrosis, today announces a proposed financing package to raise $30 million through the issue of $29 million of sterling denominated convertible loan notes to funds managed or advised by Redmile Group and Sofinnova Partners (through its investment fund Sofinnova Crossover I SLP). This financing follows the recent successful close of a mandatory offer for Redx by RM Special Holdings 3 LLC, a special purpose vehicle wholly-owned by funds managed or advised by Redmile, which resulted, on 1 May 2020, in Redmile owning 91.77 per cent. of the existing issued share capital of Redx. Prior to the offer, Redmile had already provided Redx with funding through an initial share subscription of £1.3 million and £5 million of short-term debt funding.
The net proceeds of the Loan and share subscription announced today will be used to repay the £5 million short-term debt owed to Redmile and to progress the Company’s drug development programmes in oncology and fibrosis to key value inflection points, including its lead oncology asset, RXC004, which continues to progress as planned in an ongoing phase 1 clinical study. The remaining funds will augment general working capital, serving to extend the Company’s cash runway into the third quarter of 2021.
Attraqt 27.5p £49.5m (ATQT.L)
AGM Statement. Update on the resilient performance delivered by the Group across April, May and June.
“With our teams operating from home and continuing to service our customers , the influence of Covid-19 on trading has continued to be limited. The Company’s recurring revenue model, with many customers on multi-year contracts, has served the company well and recurring license-based revenues have remained stable. Whilst increased uncertainty has meant that naturally, decision making during the pandemic has been significantly slower, impacting new bookings, the pipeline remains healthy and engagement with our current customers has never been stronger.
A number of retailers and industry experts have noted that COVID-19 appears to have accelerated the adoption of online shopping and are forecasting that that the online channel will be of greater relative importance and will receive investment going forward. This bodes well for Attraqt.”
Oriole Resources 0.325p £2.5m (ORR.L)
The exploration company focussed on West Africa, has raised £419,500 at 0.3p. The Placing Price represents a 14% discount to the price of the Company’s Ordinary Shares at close of market on 29 June 2020, and a 11% discount to the 30-day Volume Weighted Average Price . The Proceeds, will primarily be used to support ongoing exploration at the Company’s projects in Cameroon, including moving the programme at Bibemi towards drill mobilisation later this year. It will also provide the Company with general working capital, whilst management continues to deliver on its asset realisation programme as previously referenced in announcements dated 14 November 2019 and 25 February 2020.
Immunodiagostic Systems 280p £80.6m (IDH.L)
The specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 12 June, its fully automated SARS-CoV-2 IgG antibody test will be available for sale from today.
The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. IDH has commenced the process of working with various national reference centres and governmental bodies to ensure a roll-out according to national guidelines.
Erris Resources 6.1p £2.37m (ERIS.L)
Erris will resume fieldwork at the Loch Tay gold project in Scotland starting in July 2020.
- Fieldwork to resume at the expanded Lead Trial prospect where the Company recently announced that it had sampled high-grade gold in boulders and subcrop
- GreenOre Gold and Erris Resources have agreed to extend the option period by 98 days due to lost time caused by the Covid-19 restrictions
Comptoir Group 4.75p £5.83m (COM.L)
The owner and/or operator of Lebanese and Eastern Mediterranean restaurants, can confirm it plans to start re-opening some of its restaurants from 4th July 2020.
Following the government announcement on Tuesday 23rd June, Comptoir will reopen its venues in phases and in line with recommended safety guidelines. At this stage, the Group has not completed its review as to which restaurants it may decide never to re-open.
As reported at the full year results of the Company, the Group went into the COVID-19 pandemic with 30 restaurants, including six franchised sites. The Directors are in discussions with all its restaurant landlords about future lease obligations. The Directors expect the outcome of these discussions and the support it receives from landlords to influence how many restaurants the Company operates going forward. The Company will provide further updates as appropriate.
Renalytix 530p £315m (RENX.L)
The artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces a partnership with the University of Michigan to extend the application of the KidneyIntelX™ platform to an expanded population of patients with established Chronic Kidney Disease (CKD) or at risk of developing CKD. RenalytixAI also announces a data sharing agreement with a top ten global pharmaceutical company.
- Collaboration with University of Michigan provides access to novel biomarker technology and to the C-PROBE cohort for potential expanded indications for KidneyIntelX
- Data sharing agreement with top ten global pharmaceutical company enables investigation of repeat testing with KidneyIntelX and prediction of therapeutic response
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.